Derek Archila
Stock Analyst at Wells Fargo
(4.19)
# 662
Out of 4,502 analysts
128
Total ratings
45.65%
Success rate
16.33%
Average return
Main Sectors:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLRN Acelyrin | Upgrades: Overweight | $13 | $6.79 | +91.46% | 3 | Jul 8, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $478 → $542 | $480.16 | +12.88% | 7 | Jun 24, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Equal-Weight | $29 → $9 | $4.44 | +102.70% | 3 | Jun 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $57 → $48 | $38.25 | +25.49% | 8 | May 23, 2024 | |
| ANNX Annexon | Maintains: Overweight | $12 → $10 | $6.23 | +60.51% | 3 | May 15, 2024 | |
| CCCC C4 Therapeutics | Maintains: Equal-Weight | $7 → $8 | $6.70 | +19.40% | 4 | May 9, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $63 → $60 | $30.00 | +100.00% | 4 | May 9, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $14 → $12 | $10.72 | +11.94% | 3 | May 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $260 → $262 | $135.83 | +92.90% | 10 | May 3, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $53 → $52 | $49.84 | +4.33% | 4 | Apr 18, 2024 | |
| ANAB AnaptysBio | Initiates: Overweight | $56 | $38.75 | +44.52% | 1 | Apr 11, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $34 → $35 | $6.94 | +404.32% | 5 | Mar 22, 2024 | |
| MOR MorphoSys AG | Downgrades: Equal-Weight | $17 → $18 | $18.14 | +0.61% | 4 | Mar 14, 2024 | |
| VTYX Ventyx Biosciences | Upgrades: Overweight | $7 → $16 | $2.90 | +451.72% | 3 | Mar 12, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $23 → $20 | $21.94 | -8.84% | 4 | Feb 16, 2024 | |
| KYMR Kymera Therapeutics | Downgrades: Equal-Weight | $26 | $44.24 | -41.23% | 5 | Dec 19, 2023 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $86 → $115 | $113.59 | +1.24% | 7 | Dec 19, 2023 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $4 → $2 | $0.66 | +202.89% | 8 | Nov 14, 2023 | |
| CLDX Celldex Therapeutics | Upgrades: Equal-Weight | $27 | $46.41 | -41.82% | 2 | Nov 10, 2023 | |
| IMVT Immunovant | Maintains: Overweight | $33 → $48 | $28.74 | +67.04% | 8 | Sep 27, 2023 | |
| MORF Morphic Holding | Maintains: Overweight | $67 → $80 | $56.59 | +41.38% | 5 | Apr 25, 2023 | |
| EXEL Exelixis | Initiates: Overweight | $23 | $23.12 | -0.52% | 1 | Mar 9, 2023 | |
| INCY Incyte | Maintains: Equal-Weight | $72 → $75 | $69.36 | +8.13% | 3 | Jan 3, 2023 | |
| GLUE Monte Rosa Therapeutics | Upgrades: Overweight | $19 | $4.70 | +304.26% | 2 | Jan 3, 2023 | |
| ESPR Esperion Therapeutics | Downgrades: Hold | n/a | $2.45 | - | 1 | May 5, 2021 | |
| LUMO Lumos Pharma | Upgrades: Buy | n/a | $1.57 | - | 1 | Mar 11, 2021 | |
| IVA Inventiva | Initiates: Buy | n/a | $2.37 | - | 1 | Aug 4, 2020 | |
| GNFT Genfit | Upgrades: Buy | n/a | $4.52 | - | 1 | Jul 23, 2020 | |
| GLPG Galapagos NV | Downgrades: Hold | n/a | $27.50 | - | 1 | Jul 10, 2020 | |
| OKE ONEOK | Reiterates: Buy | n/a | $81.93 | - | 1 | Apr 15, 2020 | |
| AMRN Amarin Corporation | Maintains: Hold | n/a | $0.80 | - | 2 | Mar 31, 2020 | |
| DBVT DBV Technologies | Downgrades: Hold | $36 → $12 | $0.97 | +1,138.90% | 3 | Mar 17, 2020 | |
| VNDA Vanda Pharmaceuticals | Downgrades: Perform | n/a | $6.20 | - | 4 | Dec 11, 2018 | |
| HRTX Heron Therapeutics | Maintains: Outperform | n/a | $3.10 | - | 2 | Jun 22, 2018 | |
| URGN UroGen Pharma | Maintains: Outperform | n/a | $16.40 | - | 1 | Nov 15, 2017 | |
| PRGO Perrigo Company | Initiates: Outperform | n/a | $28.12 | - | 1 | Sep 7, 2017 | |
| PCRX Pacira BioSciences | Initiates: Market Perform | n/a | $20.31 | - | 1 | Sep 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Perform | n/a | $16.93 | - | 1 | Aug 3, 2017 |
Acelyrin
Jul 8, 2024
Upgrades: Overweight
Price Target: $13
Current: $6.79
Upside: +91.46%
argenx SE
Jun 24, 2024
Maintains: Overweight
Price Target: $478 → $542
Current: $480.16
Upside: +12.88%
Zentalis Pharmaceuticals
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29 → $9
Current: $4.44
Upside: +102.70%
Apellis Pharmaceuticals
May 23, 2024
Maintains: Equal-Weight
Price Target: $57 → $48
Current: $38.25
Upside: +25.49%
Annexon
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $6.23
Upside: +60.51%
C4 Therapeutics
May 9, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $6.70
Upside: +19.40%
Arvinas
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $30.00
Upside: +100.00%
Zymeworks
May 3, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $10.72
Upside: +11.94%
Ascendis Pharma
May 3, 2024
Maintains: Overweight
Price Target: $260 → $262
Current: $135.83
Upside: +92.90%
Rhythm Pharmaceuticals
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $49.84
Upside: +4.33%
AnaptysBio
Apr 11, 2024
Initiates: Overweight
Price Target: $56
Current: $38.75
Upside: +44.52%
Cabaletta Bio
Mar 22, 2024
Maintains: Overweight
Price Target: $34 → $35
Current: $6.94
Upside: +404.32%
MorphoSys AG
Mar 14, 2024
Downgrades: Equal-Weight
Price Target: $17 → $18
Current: $18.14
Upside: +0.61%
Ventyx Biosciences
Mar 12, 2024
Upgrades: Overweight
Price Target: $7 → $16
Current: $2.90
Upside: +451.72%
Nurix Therapeutics
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $21.94
Upside: -8.84%
Kymera Therapeutics
Dec 19, 2023
Downgrades: Equal-Weight
Price Target: $26
Current: $44.24
Upside: -41.23%
Blueprint Medicines
Dec 19, 2023
Maintains: Overweight
Price Target: $86 → $115
Current: $113.59
Upside: +1.24%
Kezar Life Sciences
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $0.66
Upside: +202.89%
Celldex Therapeutics
Nov 10, 2023
Upgrades: Equal-Weight
Price Target: $27
Current: $46.41
Upside: -41.82%
Immunovant
Sep 27, 2023
Maintains: Overweight
Price Target: $33 → $48
Current: $28.74
Upside: +67.04%
Morphic Holding
Apr 25, 2023
Maintains: Overweight
Price Target: $67 → $80
Current: $56.59
Upside: +41.38%
Exelixis
Mar 9, 2023
Initiates: Overweight
Price Target: $23
Current: $23.12
Upside: -0.52%
Incyte
Jan 3, 2023
Maintains: Equal-Weight
Price Target: $72 → $75
Current: $69.36
Upside: +8.13%
Monte Rosa Therapeutics
Jan 3, 2023
Upgrades: Overweight
Price Target: $19
Current: $4.70
Upside: +304.26%
Esperion Therapeutics
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.45
Upside: -
Lumos Pharma
Mar 11, 2021
Upgrades: Buy
Price Target: n/a
Current: $1.57
Upside: -
Inventiva
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $2.37
Upside: -
Genfit
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.52
Upside: -
Galapagos NV
Jul 10, 2020
Downgrades: Hold
Price Target: n/a
Current: $27.50
Upside: -
ONEOK
Apr 15, 2020
Reiterates: Buy
Price Target: n/a
Current: $81.93
Upside: -
Amarin Corporation
Mar 31, 2020
Maintains: Hold
Price Target: n/a
Current: $0.80
Upside: -
DBV Technologies
Mar 17, 2020
Downgrades: Hold
Price Target: $36 → $12
Current: $0.97
Upside: +1,138.90%
Vanda Pharmaceuticals
Dec 11, 2018
Downgrades: Perform
Price Target: n/a
Current: $6.20
Upside: -
Heron Therapeutics
Jun 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.10
Upside: -
UroGen Pharma
Nov 15, 2017
Maintains: Outperform
Price Target: n/a
Current: $16.40
Upside: -
Perrigo Company
Sep 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $28.12
Upside: -
Pacira BioSciences
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $20.31
Upside: -
Teva Pharmaceutical
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.93
Upside: -